ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors

Bähr,Oliver; Gross,Stefanie; Harter,Patrick  N.; Kirches,Elmar; Mawrin,Christian; Steinbach,Joachim  P.; Mittelbronn,Michel

doi:10.3892/ol.2017.6832

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors

Authors:
- Oliver Bähr
- Stefanie Gross
- Patrick N. Harter
- Elmar Kirches
- Christian Mawrin
- Joachim P. Steinbach
- Michel Mittelbronn
View Affiliations

Affiliations: Dr. Senckenberg Institute of Neurooncology, Goethe-University Hospital, Frankfurt, Germany, Institute of Neurology (Edinger-Institute), Goethe-University, Frankfurt, Germany, Institute of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany
Published online on: August 28, 2017 https://doi.org/10.3892/ol.2017.6832
Pages: 5443-5451
Copyright: © Bähr et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant brain tumors, including gliomas, brain metastases and anaplastic meningiomas, are associated with poor prognosis, and represent an unmet medical need. ASA404 (DMXAA), a vascular disrupting agent, has demonstrated promising results in several preclinical tumor models and early phase clinical trials. However, two phase III trials in non-small cell lung cancer reported insufficient results. The aim of the present study was to determine the effects of ASA404 on brain tumors. The effects of ASA404 were evaluated in vitro and in vivo using subcutaneous, and orthotopical models for malignant glioma (U-87, LN-229, U-251, LN-308 and Tu-2449), brain metastasis (HT-29) and malignant meningioma (IOMM-Lee). The acute effects of ASA404 on tumor tissue were analyzed using conventional and immunohistochemical staining techniques [hematoxylin and eosin, MIB-1 antibody/proliferation maker protein Ki-67, cleaved caspase-8, stimulator of interferon genes (STING), ionized calcium-binding adapter molecule 1]. Furthermore, the sizes of subcutaneous tumors were measured and the symptom-free survival rates of animals with intracranial tumors receiving ASA404 treatment were analyzed. ASA404 demonstrated low toxicity in vitro, but exhibited strong effects on subcutaneous tumors 24 h following a single dose of ASA404 (25 mg/kg). ASA404 induced necrosis, hemorrhages and inhibited the proliferation, and growth of tumors in the subcutaneous glioma models. However, ASA404 failed to demonstrate comparable effects in any of the intracranial tumor models examined and did not result in a prolongation of survival. Expression of STING, the molecular target of ASA404, and infiltration of macrophages, the cells mediating ASA404 activity, did not differ between subcutaneous and intracranial tumors. In conclusion, ASA404 demonstrates clear efficacy in subcutaneous tumor models, but has no relevant activity in orthotopic brain tumor models. The expression of STING and infiltration with macrophages were not determined to be involved in the differential activity observed among tumor models. It is possible that the low penetration of ASA-404 into the brain prevents concentrations sufficient enough reaching the tumor in order to exhibit acute effects in vivo.

View Figures

View References

1	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
3	Preusser M, Hassler M, Birner P, Rudas M, Acker T, Plate KH, Widhalm G, Knosp E, Breitschopf H, Berger J and Marosi C: Microvascularization and expression of VEGF and its receptors in recurring meningiomas: Pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 31:352–360. 2012. View Article : Google Scholar : PubMed/NCBI
4	Takano S: Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 29:73–86. 2012. View Article : Google Scholar : PubMed/NCBI
5	Batchelor TT, Reardon DA, de Groot JF, Wick W and Weller M: Antiangiogenic therapy for glioblastoma: Current status and future prospects. Clin Cancer Res. 20:5612–5619. 2014. View Article : Google Scholar : PubMed/NCBI
6	Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
7	Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
9	Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al: Phase III randomized trial comparing the efficacy of cediranib as monotherapy and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 31:3212–3218. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 28:1168–1174. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C and Combs SE: Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol. 15:1405–1412. 2013. View Article : Google Scholar : PubMed/NCBI
12	Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, et al: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15:1100–1108. 2014. View Article : Google Scholar : PubMed/NCBI
13	Baguley BC: Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4:141–148. 2003. View Article : Google Scholar : PubMed/NCBI
14	Hinnen P and Eskens FA: Vascular disrupting agents in clinical development. Br J Cancer. 96:1159–1165. 2007. View Article : Google Scholar : PubMed/NCBI
15	Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 10:415–427. 2004. View Article : Google Scholar : PubMed/NCBI
16	Tozer GM, Kanthou C and Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer. 5:423–435. 2005. View Article : Google Scholar : PubMed/NCBI
17	Folaron M, Kalmuk J, Lockwood J, Frangou C, Vokes J, Turowski SG, Merzianu M, Rigual NR, Sullivan-Nasca M, Kuriakose MA, et al: Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol. 49:893–902. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kanwar JR, Kanwar RK, Pandey S, Ching LM and Krissansen GW: Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res. 61:1948–1956. 2001.PubMed/NCBI
19	Matthews KE, Hermans IF, Roberts JM, Ching LM and Ronchese F: 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8⁺ T-cell immunotherapy. Immunol Cell Biol. 84:383–389. 2006. View Article : Google Scholar : PubMed/NCBI
20	Seshadri M and Ciesielski MJ: MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab. 29:1373–1382. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ching LM, Zwain S and Baguley BC: Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer. 90:906–910. 2004. View Article : Google Scholar : PubMed/NCBI
22	Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, et al: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8⁺ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 65:11752–11761. 2005. View Article : Google Scholar : PubMed/NCBI
23	Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11:1018–1030. 2015. View Article : Google Scholar : PubMed/NCBI
24	Corrales L, McWhirter SM, Dubensky TW Jr and Gajewski TF: The host STING pathway at the interface of cancer and immunity. J Clin Invest. 126:2404–2411. 2016. View Article : Google Scholar : PubMed/NCBI
25	Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, et al: The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med. 204:1559–1569. 2007. View Article : Google Scholar : PubMed/NCBI
26	Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P, Kortylewski M and Kline J: STING pathway activation stimulates potent immunity against acute myeloid leukemia. Cell Rep. 15:2357–2366. 2016. View Article : Google Scholar : PubMed/NCBI
27	Gao P, Ascano M, Zillinger T, Wang W, Dai P, Serganov AA, Gaffney BL, Shuman S, Jones RA, Deng L, et al: Structure-function analysis of STING activation by c[G (2′,5′)pA (3′,5′)p] and targeting by antiviral DMXAA. Cell. 154:748–762. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ishikawa H and Barber GN: STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 455:674–678. 2008. View Article : Google Scholar : PubMed/NCBI
29	Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, Rathinam VA, Monks B, Jin T, Xiao TS, et al: Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol. 190:5216–5225. 2013. View Article : Google Scholar : PubMed/NCBI
30	Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA and Vogel SN: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem. 287:39776–39788. 2012. View Article : Google Scholar : PubMed/NCBI
31	McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, et al: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 99:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
32	Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, et al: Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 29:2965–2971. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, Jassar A, Blouin A, Ching LM and Albelda SM: The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res. 67:7011–7019. 2007. View Article : Google Scholar : PubMed/NCBI
34	Smilowitz HM, Weissenberger J, Weis J, Brown JD, O'Neill RJ and Laissue JA: Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: Establishment of a new transplantable in vivo model for malignant glioma. J Neurosurg. 106:652–659. 2007. View Article : Google Scholar : PubMed/NCBI
35	Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, Angenstein F, Stork O, Kirches E and Mawrin C: Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells. Eur J Cancer. 73:9–21. 2017. View Article : Google Scholar : PubMed/NCBI
36	Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E and Mawrin C: mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res. 19:1180–1189. 2013. View Article : Google Scholar : PubMed/NCBI
37	McCutcheon IE, Friend KE, Gerdes TM, Zhang BM, Wildrick DM and Fuller GN: Intracranial injection of human meningioma cells in athymic mice: An orthotopic model for meningioma growth. J Neurosurg. 92:306–314. 2000. View Article : Google Scholar : PubMed/NCBI
38	Lee WH: Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery. 27:389–396. 1990. View Article : Google Scholar : PubMed/NCBI
39	Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, Riek-Burchardt M, Angenstein F, Reifenberger G, Riemenschneider M, et al: miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene. 32:4712–4720. 2013. View Article : Google Scholar : PubMed/NCBI
40	RayChaudhury A, Frazier WA and D'Amore PA: Comparison of normal and tumorigenic endothelial cells: Differences in thrombospondin production and responses to transforming growth factor-beta. J Cell Sci. 107:39–46. 1994.PubMed/NCBI
41	Muhlner U, Mohle-Steinlein U, Wizigmann-Voos S, Christofori G, Risau W and Wagner EF: Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene. Oncogene. 18:4200–4210. 1999. View Article : Google Scholar : PubMed/NCBI
42	Montesano R, Pepper MS, Möhle-Steinlein U, Risau W, Wagner EF and Orci L: Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 62:435–445. 1990. View Article : Google Scholar : PubMed/NCBI
43	Weller M, Rieger J, Grimmel C, Van Meir EG, Tribolet N, De Krajewski S, Reed JC, von Deimling A and Dichgans J: Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. Int J Cancer. 79:640–644. 1998. View Article : Google Scholar : PubMed/NCBI
44	Yung R, Seyfoddin V, Guise C, Tijono S, McGregor A, Connor B and Ching LM: Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Cancer Chemother Pharmacol. 73:639–649. 2014. View Article : Google Scholar : PubMed/NCBI
45	Renner DN, Jin F, Litterman AJ, Balgeman AJ, Hanson LM, Gamez JD, Chae M, Carlson BL, Sarkaria JN, Parney IF, et al: Effective treatment of established GL261 murine gliomas through picornavirus vaccination-enhanced tumor antigen-specific CD8⁺ T cell responses. PLoS One. 10:e01255652015. View Article : Google Scholar : PubMed/NCBI
46	Zhao L, Ching LM, Kestell P and Baguley BC: The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer. 87:465–470. 2002. View Article : Google Scholar : PubMed/NCBI
47	Conlon J, Burdette DL, Sharma S, Bhat N, Thompson M, Jiang Z, Rathinam VA, Monks B, Jin T, Xiao TS, et al: Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol. 190:5216–5225. 2013. View Article : Google Scholar : PubMed/NCBI